Trial Profile
A prospective randomized open-label blinded-endpoint (PROBE) trial comparing Micardis (telmisartan) (40-80-80 mg QD) and ramipril (2.5-5-10 mg QD) in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring (ABPM)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Dec 2023
Price :
$35
*
At a glance
- Drugs Telmisartan (Primary) ; Ramipril
- Indications Hypertension
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 29 Mar 2007 New trial record.